Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model.

Date publication

janvier 2025

Journal

EBioMedicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François , Dr DERANGERE Valentin

Tous les auteurs :
Fournier C, Mercey-Ressejac M, Derangère V, Al Kadi A, Rageot D, Charrat C, Leroy A, Vollaire J, Josserand V, Escudé M, Escaich S, Ghiringhelli F, Decaens T, Navarro FP, Jouvin-Marche E, Marche PN

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39793480

Résumé

mRNA-based cancer vaccines show promise in triggering antitumour immune responses. To combine them with existing immunotherapies, the intratumoral immune microenvironment needs to be deeply characterised. Here, we test nanostructured lipid carriers (NLCs), the so-called Lipidots®, for delivering unmodified mRNA encoding Ovalbumin (OVA) antigen to elicit specific antitumour responses.

Mots clés

Cancer, Immune checkpoint inhibitor, Innate immunity, Memory immunity, T cells, mRNA vaccine

Référence

EBioMedicine. 2025 01 9;112:105543